Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Microencapsulation Market Revenue to Attain USD 35.30 Bn by 2033
The microencapsulation market, valued at USD 14.47 billion in 2024, is projected to reach USD 35.30 billion by 2033, growing at a CAGR of 10.42%. This growth is driven by increased demand in pharmaceutical, food, and agrochemical industries. Key trends include the rising adoption of phase change materials and controlled-release drug delivery systems. North America leads the market, while Asia Pacific shows the fastest growth.
How HIV Research Reshaped Modern Medicine
HIV research transformed from a death sentence to a manageable condition, impacting COVID-19, cancer treatments, and vaccine development. Key insights include HIV's rapid mutation, integration into host DNA, and immune evasion, driving advancements in antiretroviral therapy and pre-exposure prophylaxis. Elite controllers' immune responses offer hope for a vaccine, with ongoing trials in Africa and South Africa.
Antibiotics and Antimycotics Market Size to Hit $91.54 Billion, Globally at 5.2% CAGR by 2031
The antibiotics and antimycotics market is projected to reach $91.54 billion by 2031, driven by infectious disease prevalence and R&D initiatives. Key players include Pfizer, Novartis, and Sanofi. North America leads in revenue, with APAC expected to show highest growth.
Microencapsulation Market Size to Surpass USD 38.98 Bn by 2034
The global microencapsulation market is projected to grow from USD 14.47 billion in 2024 to USD 38.98 billion by 2034, driven by increased attention and benefits of the technology. North America dominated in 2023, while Asia Pacific is expected to grow fastest. Key segments include pharmaceutical and healthcare products, food and beverage, and polymer and carbohydrate coating materials. AI is impacting the market by streamlining processes and enhancing accuracy. The U.S. market is forecast to grow from USD 3.75 billion in 2024 to USD 10.31 billion by 2034.
Formycon reports nine-month results for 2024 and continues growth trajectory with further ...
Formycon reports nine-month results for 2024, highlighting product approvals for FYB202 in the USA and Europe, the start of clinical development for Keytruda® biosimilar FYB206, and the initiation of FYB210 development. Financial results reflect successful business performance, confirming guidance.
Pharmaceutical CDMO Market Size Projected to Reach USD 368.70 Bn by 2034
The global pharmaceutical CDMO market was valued at USD 184.90 billion in 2024 and is projected to reach USD 368.70 billion by 2034, driven by a CAGR of 7.2%. Key players include Pfizer, Biocon Biologics, and Thermo Fisher Scientific. Services offered by CDMOs include antibody production and vaccine development, operating under GMP and cGMP standards. The Asia Pacific region leads with a 42.4% market share, while Europe is expected to grow at a CAGR of 7.7%.
How HIV research has reshaped modern medicine
HIV research has transformed the infection from a death sentence into a manageable chronic condition, affecting 1.2 million people in the U.S. and nearly 40 million worldwide. Key advancements include antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP), with ongoing efforts focused on developing a vaccine. Insights from HIV research have also significantly influenced the development of COVID-19 vaccines and treatments for other diseases.
Gene Switch Market Impacts on Medicine and Biotechnology Sector
The Gene Switch Market is projected to grow from USD 0.78 Bn in 2024 to USD 1.78 Bn by 2031, with a CAGR of 11.6%. CoherentMI's report provides a comprehensive analysis of market trends, competitive landscape, and key players like Novartis, Pfizer, and Gilead Sciences.
FDA's Psychedelic Reckoning
Psychedelic drug developers face setbacks but see potential in Johnson & Johnson's Spravato success. Cybin, a Toronto-based company, benefits from FDA insights gained from Lykos and Compass's issues, advancing its Phase 3 trial for deuterated psilocin (CYB003) for major depressive disorder. Cybin emphasizes FDA-desired trial details and patient safety measures, leveraging breakthrough therapy designation for real dialogue with the agency. The expanding infrastructure for Spravato administration supports future psychedelic drug rollouts.
Allergy Relieving Eye Drops Market Global Forecast Report
The Allergy Relieving Eye Drops Market is projected to grow from USD 1.51 billion in 2023 to USD 2.37 billion by 2032, driven by rising allergy prevalence, demand for non-invasive solutions, and advancements in eye drop formulations. Key markets include Canada, France, India, and UAE, with major companies like AbbVie, Johnson & Johnson, and Pfizer leading the industry.
© Copyright 2024. All Rights Reserved by MedPath